Eisai Schedules Filings For Thyroid Cancer Drug In Three Largest Markets
This article was originally published in PharmAsia News
Executive Summary
Eisai said it intends to file for marketing approval for its E7080 (lenvatinib) drug for treating thyroid cancer in the world's three largest markets, the U.S., Europe and Japan, by September.